Open AccessCurrent progress and outcomes of clinical trials on using epidermal growth factor receptor‐tyrosine kinase inhibitor therapy in non‐small cell lung cancer patients with brain metastases
Author(s) -
Kong LingLing,
Wang LinLin,
Xing LiGang,
Yu JinMing
Publication year - 2017
Publication title -
chronic diseases and translational medicine
Language(s) - English
Resource type - Journals
ISSN - 2589-0514
DOI - 10.1016/j.cdtm.2017.11.001
Subject(s) - medicine , osimertinib , lung cancer , brain metastasis , epidermal growth factor receptor , oncology , tyrosine kinase inhibitor , clinical trial , tyrosine kinase , metastasis , radiation therapy , targeted therapy , cancer , erlotinib , cancer research , receptor
Non‐small cell lung cancer (NSCLC) continues to be one of the major causes of cancer‐related deaths worldwide, and brain metastases are the major cause of death in NSCLC patients. With recent advances in understanding the underlying molecular mechanism of NSCLC development and progression, mutations in epidermal growth factor receptor ( EGFR ) have been recognized as a key predictor of therapeutic sensitivity to EGFR tyrosine kinase inhibitors (TKIs). Using EGFR‐TKI alone or in combination with standard treatments such as whole‐brain radiotherapy and surgery has been an effective strategy for the management of brain metastasis. Particularly, a newer generation of EGFR‐TKIs, including osimertinib and AZD3759, has been developed. These new EGFR‐TKIs can cross the blood–brain barrier and potentially treat EGFR‐TKI resistance and improve prognosis. In this article, current progress and outcomes of clinical trials on the use of EGFR‐TKIs for treating NSCLC patients with brain metastasis will be reviewed.